Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia (NCT03971799)
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design, with dose-escalation for autologous products separated from dose-escalation for an allogeneic arm. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital of Los Angeles — Los Angeles, California
Age range: 1 Year to 35 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Children's Hospital of Los Angeles — Los Angeles, California
- Children's Hospital of Colorado — Aurora, Colorado
- National Cancer Institute - NIH — Bethesda, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Seattle Children's Hospital/Fred Hutchinson Cancer Research Center — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myelogenous Leukemia
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients — Boston, Massachusetts
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission — Boston, Massachusetts
- Allo HSCT Using RIC and PTCy for Hematological Diseases — Minneapolis, Minnesota
- ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Cleveland, Ohio
- Cord Blood Transplantation in Children and Young Adults With Blood Cancer — New York, New York
Explore by condition: All Acute Myelogenous Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.